title: [Expression of PD4, CD44v6, CD44v9 and its clinical significance in human laryngeal carcinoma].
abstract: OBJECTIVE
  Study on the role of mycoplasma infection and expression of CD44v6, CD44v9 protein in the pathogenesis, development and prognosis of laryngeal carcinoma (LC).
  
  
  METHODS
  Immunohistochemistry was used to study 137 cases of laryngeal carcinoma tissues, 26 cases of precarcinoma tissues, 34 cases of vocal cord polypus and 15 cases of normal tissues adjacent to laryngeal carcinoma.
  
  
  RESULTS
  The positive rate of PD4 and CD44v6, CD44v9 was 45.3% (62/137), 72.3% (99/137) and 56.2% (77/137) in laryngeal carcinoma, which are much higher than those in non-carcinoma tissues. (2) The positive rate of PD4 and CD44v6. CD44v9 in the third and fourth stages of LC were higher than those in the first and second stages of LC. Laryngeal carcinoma with cervical metastasis had higher expression than those without cervical metastasis (P < 0.01). To 3 and 5 years survival, PD4 and CD44v6, CD44v9 positive cases had lower chance than those negative cases (P < 0.01 [Chinese character: see text] 0.05). (3) The overall positive rate of PD4 and CD44v6, CD44v9 was 27.7% (38/137) in laryngeal carcinoma tissues and 5.3% (4/75) in non-carcinoma tissues.
  
  
  CONCLUSIONS
  These results implicates that the pathogenesis, development and prognosis of laryngeal carcinoma maybe closely related to the high expression of PD4 and CD44v6, CD44v9 protein.
authors.affiliation: Department of Otolaryngology, the First Affiliated Hospital of PLA General Hospital, Beijing, 100037, China.
authors.forename: Baochun
authors.initials: B
authors.lastname: Sun
authors.forename: Shuwei
authors.initials: S
authors.lastname: Zhao
authors.forename: Dagen
authors.initials: D
authors.lastname: Liu
authors.forename: Chengyong
authors.initials: C
authors.lastname: Zhou
authors.forename: Qinghong
authors.initials: Q
authors.lastname: Yan
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000096:biosynthesis*; D051017:Apoptosis Regulatory Proteins / Q000378:metabolism*; D002294:Carcinoma, Squamous Cell / Q000378:metabolism* / Q000382:microbiology / Q000473:pathology; D005260:Female; D006801:Humans; D018960:Hyaluronan Receptors / Q000378:metabolism*; D007822:Laryngeal Neoplasms / Q000378:metabolism* / Q000382:microbiology / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009174:Mycoplasma / Q000276:immunology; D009367:Neoplasm Staging; D011379:Prognosis; D016601:RNA-Binding Proteins / Q000378:metabolism*
chemical_list: D000911:Antibodies, Monoclonal; D051017:Apoptosis Regulatory Proteins; C112697:CD44v6 antigen; C448906:CD44v9 antigen; D018960:Hyaluronan Receptors; C114487:PDCD4 protein, human; D016601:RNA-Binding Proteins